Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LX2022
- Development stage
- Preclinical
- Lead developer
- Lexeo Therapeutics
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
LX2022 is a gene therapy candidate being developed to deliver a functional TNNI3 gene to myocardial cells for the treatment of hypertrophic cardiomyopathy (HCM) caused by mutations in the TNNI3 gene. HCM is a genetic disorder characterized by left ventricular hypertrophy and cardiac muscle dysfunction, with TNNI3 mutations accounting for approximately 5% of cases. The therapy aims to restore normal function in affected myocardial cells by providing a working copy of the TNNI3 gene. LX2022 is currently in preclinical development and targets patients with this distinct genetic form of HCM[1][2][3].
- Other names
- TNNI3 HCMTNNI-3 HCMTNNI 3 HCM
02
Targets
cTnI (Troponin I type 3 (cardiac))
Beyond the preview
Go deeper on LX2022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LX2022.